<DOC>
	<DOCNO>NCT00001504</DOCNO>
	<brief_summary>This dosage escalation study estimate maximum tolerate dose 9-cis-retinoic acid give combination tamoxifen . Groups 3 6 patient receive oral 9-cis-retinoic acid daily 4 week , daily oral tamoxifen add regimen . Patients continue treatment 28 week , tamoxifen continue study medically appropriate .</brief_summary>
	<brief_title>A Phase I Trial Tamoxifen 9-Cis-Retinoic Acid Breast Cancer Patients</brief_title>
	<detailed_description>This Phase I study combination tamoxifen 9-cis-Retinoic acid patient breast cancer . The primary objective study ; 1 ) determine maximum tolerate dose 9-cis-Retinoic acid combination Tamoxifen determine overall dose limit toxicity . Other objective : 2 ) determine effect Tamoxifen pharmacokinetics 9-cis-Retinoic acid ; 3 ) evaluate anti-tumor activity combination therapy within context phase I study ; 4 ) determine expression surrogate biomarkers breast carcinogenesis treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Alitretinoin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : All patient must histologically document diagnosis Stage III , IV breast carcinoma . Patients stage III complete chemotherapy : Estrogen receptor ( ER ) progesterone receptor ( PR ) positive tumor require premenopausal . Either ER/PRpositive negative tumor allow postmenopausal receive prior chemotherapy . Patients may stage IV ER/PRpositive negative tumor . No CNS metastasis , pseudotumor cereri , seizure . PRIOR/CONCURRENT THERAPY : Patients ecovered toxic effect prior therapy eligible . Patients prior tamoxifen allow participate . At least 3 week must elapse since last dose chemotherapy . PATIENT CHARACTERISTICS : Age : 18 . Sex : Men woman . Menopausal status : Any status . Patients must performance status ECOG 02 . Patients must Hematopoietic criterion : ANC least 1,500/mm ( 3 ) . Platelet count least 90,000/mm ( 3 ) . Patients must Hepatic criterion : In absence tumor involvement : Bilirubin great twice normal ; SGOT great twice normal ; Alkaline phosphate great twice normal ; Fasting triglyceride le 3 time normal . Patients must Renal criterion : Serum creatinine great 1.5 mg/dL OR ; Creatinine clearance least 60 mL/min . Other : No allergy study medication . No nonmalignant systemic disease would preclude therapy . No second malignancy within 5 year except : Curatively treat basal cell skin carcinoma . Cervical carcinoma situ . Pregnant woman exclude . Negative pregnancy test require within 7 day prior entry . Adequate contraception require 4 week prior , , 1 year study . Patients must give informed consent . Patients poor medical psychiatric risk eligible .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>Retinoids</keyword>
	<keyword>Biomarkers</keyword>
</DOC>